BioCentury | Dec 15, 2014
Company News

Potentia, Apellis deal

...Apellis is acquiring Potentia for an undisclosed sum. The deal includes IP, which will allow Apellis...
...to treat dry age-related macular degeneration (AMD) in 1Q15. Potentia spun out Apellis in 2010. Potentia Pharmaceuticals Inc....
BioCentury | Feb 10, 2014
Emerging Company Profile

Amyndas: Complement shutdown

...first generation analogs include POT-4 , which was discovered in Lambris' lab and licensed to Potentia Pharmaceuticals Inc....
...companies. Novartis AG 's Alcon Inc. has exclusive rights to POT-4 in ophthalmic indications from Potentia...
...Crestwood, Ky. National Institutes of Health (NIH), Bethesda, Md. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Potentia Pharmaceuticals Inc....
BioCentury | Jan 16, 2014
Distillery Therapeutics

Indication: Autoimmune disease

...treat metastatic castration-resistant prostate cancer (CRPC) and Phase II testing to treat other solid tumors. Potentia Pharmaceuticals Inc....
BioCentury | May 9, 2013
Distillery Therapeutics

Indication: Transplantation

...A/S's anti-C5aR-151 (NN8209), an anti-C5a mAb, is in Phase I testing for rheumatoid arthritis (RA). Potentia Pharmaceuticals Inc....
BioCentury | Dec 2, 2010
Distillery Therapeutics

Indication: Musculoskeletal disease

...pathology in Dysf- mice. Next steps could include testing complement factor inhibitors in the model. Potentia Pharmaceuticals Inc.'s...
BioCentury | May 27, 2010
Distillery Therapeutics

Indication: Infectious disease

...controls. Next steps include pharmacokinetic and toxicity studies. Compstatin, a synthetic peptide C3 inhibitor from Potentia Pharmaceuticals Inc....
...the Oklahoma Medical Research Foundation Technology Transfer Office; use in ocular diseases exclusively licensed to Potentia...
BioCentury | Oct 26, 2009
Company News

Potentia, Alcon deal

...Alcon's Alcon Research Ltd. subsidiary received exclusive, worldwide rights to Potentia's POT-4 and an option to...
...and Potentia's shareholders also are eligible for milestones and royalties. Financial terms were not disclosed. Potentia Pharmaceuticals Inc....
BioCentury | Oct 24, 2009
Company News

Alcon licenses POT-4 from Potentia

...macular degeneration (AMD). Potentia will receive upfront payments for the license and option rights, and Potentia's...
BioCentury | Jun 25, 2009
Targets & Mechanisms

Seeing CNV sooner

...are no methods to detect pre-wet AMD patients," said Pascal Deschatelets, COO and cofounder of Potentia Pharmaceuticals Inc....
...aid AMD drug development, "you have to go blind in the field," said Deschatelets. Indeed, Potentia's...
...SciBX . The company's preclinical safety and toxicology studies were done in rabbits and monkeys. Potentia...
BioCentury | May 11, 2009
Clinical News

Compstatin: Phase I data

...µg achieved significant, sustained levels of POT-4 in serum. There were no serious adverse events. Potentia Pharmaceuticals Inc....
Items per page:
1 - 10 of 27
BioCentury | Dec 15, 2014
Company News

Potentia, Apellis deal

...Apellis is acquiring Potentia for an undisclosed sum. The deal includes IP, which will allow Apellis...
...to treat dry age-related macular degeneration (AMD) in 1Q15. Potentia spun out Apellis in 2010. Potentia Pharmaceuticals Inc....
BioCentury | Feb 10, 2014
Emerging Company Profile

Amyndas: Complement shutdown

...first generation analogs include POT-4 , which was discovered in Lambris' lab and licensed to Potentia Pharmaceuticals Inc....
...companies. Novartis AG 's Alcon Inc. has exclusive rights to POT-4 in ophthalmic indications from Potentia...
...Crestwood, Ky. National Institutes of Health (NIH), Bethesda, Md. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Potentia Pharmaceuticals Inc....
BioCentury | Jan 16, 2014
Distillery Therapeutics

Indication: Autoimmune disease

...treat metastatic castration-resistant prostate cancer (CRPC) and Phase II testing to treat other solid tumors. Potentia Pharmaceuticals Inc....
BioCentury | May 9, 2013
Distillery Therapeutics

Indication: Transplantation

...A/S's anti-C5aR-151 (NN8209), an anti-C5a mAb, is in Phase I testing for rheumatoid arthritis (RA). Potentia Pharmaceuticals Inc....
BioCentury | Dec 2, 2010
Distillery Therapeutics

Indication: Musculoskeletal disease

...pathology in Dysf- mice. Next steps could include testing complement factor inhibitors in the model. Potentia Pharmaceuticals Inc.'s...
BioCentury | May 27, 2010
Distillery Therapeutics

Indication: Infectious disease

...controls. Next steps include pharmacokinetic and toxicity studies. Compstatin, a synthetic peptide C3 inhibitor from Potentia Pharmaceuticals Inc....
...the Oklahoma Medical Research Foundation Technology Transfer Office; use in ocular diseases exclusively licensed to Potentia...
BioCentury | Oct 26, 2009
Company News

Potentia, Alcon deal

...Alcon's Alcon Research Ltd. subsidiary received exclusive, worldwide rights to Potentia's POT-4 and an option to...
...and Potentia's shareholders also are eligible for milestones and royalties. Financial terms were not disclosed. Potentia Pharmaceuticals Inc....
BioCentury | Oct 24, 2009
Company News

Alcon licenses POT-4 from Potentia

...macular degeneration (AMD). Potentia will receive upfront payments for the license and option rights, and Potentia's...
BioCentury | Jun 25, 2009
Targets & Mechanisms

Seeing CNV sooner

...are no methods to detect pre-wet AMD patients," said Pascal Deschatelets, COO and cofounder of Potentia Pharmaceuticals Inc....
...aid AMD drug development, "you have to go blind in the field," said Deschatelets. Indeed, Potentia's...
...SciBX . The company's preclinical safety and toxicology studies were done in rabbits and monkeys. Potentia...
BioCentury | May 11, 2009
Clinical News

Compstatin: Phase I data

...µg achieved significant, sustained levels of POT-4 in serum. There were no serious adverse events. Potentia Pharmaceuticals Inc....
Items per page:
1 - 10 of 27